Aminolevulinic acid hydrochloride 0.1 mg/MG [Ameluz]
RxNorm 1806647

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1806647 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: aminolevulinic acid hydrochloride 0.1 mg/MG [Ameluz].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Aminolevulinic acid hydrochloride 0.1 mg/MG [Ameluz]
AUI:12303905
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Aminolevulinic acid hydrochloride 0.1 mg/MG [Ameluz]
(Atom ID: 12303905)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
aminolevulinic acid hydrochloride 0.1 MG/MG [Ameluz]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1806647
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12303905
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
1806647
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Aminolevulinic Acid Topical


Aminolevulinic acid is used in combination with photodynamic therapy (PDT; special blue light) to treat actinic keratoses (small crusty or scaly bumps or horns on or under the skin that result from exposure to sunlight and can develop into skin cancer) of the face or scalp. Aminolevulinic acid is in a class of medications called photosensitizing agents. When aminolevulinic acid is activated by light, it damages the cells of actinic keratosis lesions.
[Learn More]


* Please review the disclaimer below.